as 02-10-2025 10:40am EST
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
Founded: | 2016 | Country: | Canada |
Employees: | N/A | City: | SAINT-LAURENT |
Market Cap: | 54.4M | IPO Year: | 2020 |
Target Price: | $7.00 | AVG Volume (30 days): | 355.4K |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.99 | EPS Growth: | N/A |
52 Week Low/High: | $1.10 - $8.49 | Next Earning Date: | 02-26-2025 |
Revenue: | $66,524,000 | Revenue Growth: | 18.19% |
Revenue Growth (this year): | 11.8% | Revenue Growth (next year): | -88.02% |
RPTX Breaking Stock News: Dive into RPTX Ticker-Specific Updates for Smart Investing
Zacks
17 days ago
Zacks
20 days ago
MT Newswires
a month ago
Business Wire
a month ago
MT Newswires
2 months ago
Benzinga
2 months ago
GuruFocus.com
2 months ago
Clinical Trials Arena
2 months ago
The information presented on this page, "RPTX Repare Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.